Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
87.00
+5.70 (7.01%)
At close: Feb 26, 2026
Market Cap 11.68B
Revenue (ttm) 1.03M
Net Income (ttm) -1.36B
Shares Out 134.28M
EPS (ttm) -57.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,761,272
Average Volume 2,142,613
Open 81.00
Previous Close 81.30
Day's Range 78.40 - 92.20
52-Week Range 37.55 - 92.20
Beta n/a
RSI 88.03
Earnings Date n/a

About TPEX:7871

Elixiron Immunotherapeutics (Cayman) Limited engages in the development of precision-targeted immunotherapy drugs in Shanghai, Taipei, the United States and Switzerland. It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and Hemophagocytic Lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer. Elixiron Immunotherapeutics (Cayman) Limited was incorporated in 2017 and is he... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 7871
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.